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Abstract 
Background: In malaria endemic regions in Kenya, pregnant women are offered long-lasting insecticidal nets and 
intermittent preventive treatment (IPTp) with sulfadoxine–pyrimethamine (SP) at antenatal care (ANC) to prevent the 
adverse effects of malaria. Fears of growing SP resistance have heightened the search for alternative strategies. The 
implementation feasibility of intermittent screening and treatment (ISTp) with dihydroartemisinin–piperaquine (DP) in 
routine ANC settings was evaluated using qualitative and quantitative methods, including the exploration of health-
care provider and pregnant women’s perceptions.
Methods: Qualitative methods included data from 13 focus group discussions (FGDs) with pregnant women and 43 
in-depth interviews with healthcare providers delivering ANC services. FGDs were conducted with women who had 
received either ISTp-DP or current policy (IPTp-SP). Thematic analysis was used to explore experiences among women 
and providers and findings were used to provide insights into results of the parallel quantitative study.
Results: Women were accepting of testing with rapid diagnostic tests (RDTs) and receiving treatment if malaria 
positive. Providers perceived DP to be an effective drug and well tolerated by women. Some providers indicated a 
preference for test and treat strategies to reduce unnecessary exposure to medication in pregnancy, others preferred 
a hybrid strategy combining screening at every ANC visit followed by IPTp-SP for women who tested negative, due to 
the perception that RDTs missed some infections and concerns about the growing resistance to SP. Testing with RDTs 
during ANC was appreciated as it was perceived to reduce wait times. The positive attitude of healthcare providers 
towards ISTp supports findings from the quantitative study that showed a high proportion (90%) of women were 
tested at ANC. There were concerns about affordability of DP and the availability of sufficient RDT stocks.
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Background
Malaria in pregnancy (MiP) is associated with poor 
health outcomes for both mother and baby, with a high 
number of low birthweight deliveries attributed to MiP 
[1]. The World Health Organization (WHO) currently 
recommends intermittent preventive treatment with 
sulfadoxine–pyrimethamine (IPTp-SP), use of long-
lasting insecticidal nets (LLINs) and effective case man-
agement as interventions to reduce MiP and they  are 
primarily delivered through the antenatal care  (ANC) 
platform. However, against the backdrop of declining 
transmission rates across much of Kenya and the grow-
ing threat of SP resistance, the Division of National 
Malaria Programme (DNMP) has recently shifted 
the policy for control of MiP from IPTp-SP to passive 
case detection alongside the continued use of LLINs 
in all but three endemic provinces [2]. Where IPTp-
SP remains policy, concerns have been raised regard-
ing the possible increased risk of fetal anaemia in areas 
with high levels of SP resistance [3], although more 
recent studies indicate that SP continues to be effec-
tive in reducing low birth weight outcomes in areas of 
high resistance but is compromised in areas with highly 
resistant parasites [4]. Nevertheless, these concerns 
have accelerated the search for alternative drugs for 
IPTp or new strategies that are at least as effective in 
controlling MiP and can be implemented and delivered 
through routine ANC services.
One potential alternative strategy is intermittent 
screening and treatment (ISTp) for malaria in preg-
nancy. ISTp involves testing pregnant women at every 
ANC visit using microscopy or rapid diagnostic tests 
(RDTs) and providing treatment only to those who test 
positive, with women who test negative receiving no 
anti-malarials. ISTp has now been tested in a number of 
randomized controlled trials (RCTs) in East and West 
Africa [5, 6], Indonesia [7] and India [8] together with 
an evaluation of implementation in the routine setting 
[9] and in studies of user and provider acceptability in 
some countries [10–13]. The ISTp strategy was explored 
previously in western Kenya under trial conditions and 
was found to be broadly acceptable to both pregnant 
women and healthcare providers [12], but this will be 
the first study to examine perceptions and experiences 
of implementation in the routine setting in this region.
To complement a large RCT comparing ISTp or IPTp 
with DP against the current policy of IPTp with SP, an 
evaluation was conducted to assess the implementation 
feasibility of one of the trial interventions, ISTp-DP in 
health facilities outside of the trial setting, compared to 
implementation of the national policy, IPTp-SP. The eval-
uation included quantitative and qualitative components, 
the qualitative component reported on here was carried 
out to explore the attitudes of healthcare providers and 
pregnant women towards key elements of the ISTp strat-
egy and assess possible challenges for implementing ISTp 
under routine conditions. Findings from this study are 
used to provide insights into some of the key results from 
the parallel quantitative study.
Methods
Study site and context
The study was conducted in four sub-counties in Kisumu 
County in western Kenya—Muhoroni, Nyakach, Kisumu 
West, and Seme. At the time of the study, the popula-
tion of Kisumu County was approximately 970,000 [14]. 
Malaria transmission in this region is stable and peren-
nial. MiP guidelines for malaria endemic regions in Kenya 
include the use of LLINs (distributed through routine 
ANC channels, social marketing and mass campaigns), 
prompt diagnosis and case management of active infec-
tions, and IPTp with SP delivered via directly observed 
therapy (DOT) at every ANC visit starting in the  2nd tri-
mester and given at least 4 weeks apart with a target of 
at least 3 doses throughout the pregnancy [2, 15]. ANC 
coverage is high in the lake endemic zone, which includes 
Kisumu county, with 97.3% of pregnant women receiving 
ANC care from a skilled provider [16]. In 2015, 54.7% of 
pregnant women in the endemic lake regions received 
2 or more doses of SP, however only 35.3% received the 
recommended 3 or more doses of SP in their last preg-
nancy [16].
Intervention
Full details of the intervention implementation are 
reported in the companion paper Hill et  al. [17]. In 
Conclusion: In ANC settings, healthcare providers and pregnant women found ISTp-DP to be an acceptable strategy 
for preventing malaria in pregnancy when compared with IPTp-SP. DP was considered an effective anti-malarial and 
a suitable alternative to IPTp-SP in the context of SP resistance. Despite providers’ lack of confidence in RDT results at 
current levels of sensitivity and specificity, the quantitative findings show their willingness to test women routinely at 
ANC.
Keywords: Feasibility, Intermittent screening and treatment, Intermittent preventive treatment, Dihydroartemisinin–
piperaquine, Health system delivery, Pregnant women, Healthcare providers, Kenya
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summary, the implementation feasibility study was con-
ducted in twelve health facilities that were not involved 
in the RCT. For each strategy (IPTp-SP or ISTp-DP) 
six health facilities were selected. Health facility selec-
tion was based on (1) type of government owned facil-
ity—level 4 (district and sub-district hospitals) or level 
3 (health centres) and (2) the feasibility of achieving the 
required sample size of pregnant women attending ANC. 
Due to resource constraints, in-depth interviews (IDIs) 
with healthcare providers and focus group discussions 
(FGDs) with pregnant women were carried out in a sub-
set of the implementation facilities. Participants were 
selected from four of the six intervention health facilities 
(ISTp-DP) and four of the six control (IPTp-SP) health 
facilities. The 8 out of 12 health facilities were selected 
based on logistic and resource feasibility whilst ensur-
ing inclusion of a mix of districts and level 4 and level 3 
health facilities.
Pregnant women attending the selected health facilities 
received the usual focused ANC package and, depending 
on the study arm, either: (1) IPTp with a single dose of 
SP delivered by ANC staff via directly observed therapy 
(DOT), or (2) ISTp with DP for which women were tested 
using RDTs and if positive, provided with a first dose of 
DP by DOT and instructions to complete the 2nd and 
3rd dose of DP at home (the DP doses are taken once per 
day for 3  days). Women who tested RDT negative were 
given no anti-malarial medication. The health facilities 
were provided with sufficient RDTs [CareStart Malaria 
HRP2 (Pf ); AccessBio Inc, USA], DP, and SP for the study 
period. The RDTs provided were the same as those pro-
cured and distributed by the DNMP.
Evaluation design
The evaluation employed a mixed methods study design, 
and this paper reports on the qualitative findings. Meth-
ods used in the qualitative evaluation comprised IDIs 
with healthcare providers and FGDs with pregnant 
women in each study arm. The aim was to understand 
perceptions of both providers and pregnant women 
towards the intervention (IST-DP), specifically examin-
ing women’s acceptability of the core components of the 
interventions i.e. blood tests and adherence to drugs. The 
findings of the qualitative study were then used to inter-
pret some of the key results of the quantitative study par-
ticularly across components of the feasibility framework 
defined by Bowen et al. [18].
Participants and study procedures
The IDIs and FGDs were conducted between February 
and June 2015, six months after the pilot implementation 
of ISTp. IDIs were conducted with healthcare provid-
ers in four of the intervention (ISTp-DP) and four of the 
control (IPTp-SP) health facilities, together with County 
health management team members in all four districts. 
FGDs were conducted with pregnant women who had 
attended ANC at either the intervention or control health 
facilities.
In‑depth interviews with providers
Healthcare providers were purposively selected to 
include those involved with different elements of the 
intervention and control strategies, including health 
facility managers, ANC nurses, laboratory technicians 
and pharmacists, and County health management team 
members. Individual interviews were conducted with 
healthcare providers in English, using a semi-structured 
interview guide (Additional file  1). Interview themes 
included: (1) perceptions of the ISTp-DP strategy vs the 
current policy of IPTp-SP; (2) workplace adaptations that 
would be required if ISTp-DP were adopted, (3) recom-
mendations to ensure effective implementation of ISTp-
DP, (4) perceptions of service delivery challenges and 
opportunities with ISTp-DP (including use of RDTs in 
the ANC). Interviews were digitally recorded and tran-
scribed verbatim.
FGDs with pregnant women
FGDs were undertaken with women who had attended 
ANC in the implementation feasibility study control or 
intervention health facilities. Four categories of FGD 
were conducted including groups comprising women 
who had received either: (1) IPTp-SP; (2) ISTp-DP and 
were RDT negative; (3) ISTp-DP and were RDT positive 
at least once; or (4) either IPTp-SP or ISTp-DP—a mixed 
heterogenous group. The FGDs with pregnant women 
followed a topic guide to elucidate women’s perspectives 
and experiences with regards to ANC services, blood 
testing (finger pricks with RDTs), taking of medication 
during pregnancy (including concerns about taking SP or 
DP during pregnancy) and motivation for attending ANC 
(Additional file  2). Interviews were conducted in Luo 
and Swahili and digitally recorded, then transcribed and 
translated into English.
Data analysis
The transcripts from both IDIs and FGDs were trans-
ferred to NVivo 10 for coding and analysis. Data from the 
IDIs and FGDs were coded separately by one investiga-
tor and disagreements in the coding and analysis were 
discussed among the research team until a consensus 
was reached. The framework for analysis for healthcare 
provider IDIs included and expanded upon two pub-
lished frameworks including: (1) health systems building 
blocks (finance, governance, health information, human 
resources, products and technology, service delivery) 
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[19], (2) feasibility framework (acceptability, demand, 
implementation, practicality, integration, adaptation, 
expansion) [18], and additionally included (3) provider 
perceptions of pregnant women’s acceptance of interven-
tion components: DP vs. SP, blood testing, and ISTp-DP 
vs. IPTp-SP. Data could be coded multiple times to fit 
themes in each of the different components of the frame-
work to enable synthesized and individual analysis of the 
data.
A framework for analysis for the FGDs with pregnant 
women was developed comprising: (1) access framework 
(availability, accessibility, accommodation, affordabil-
ity, acceptability) [20], (2) perceptions of blood testing, 
(3) adherence to drugs (DP and SP), and (4) perception 
of ANC services. Here, acceptability is defined as ‘the 
extent to which an intervention (blood testing and tak-
ing DP) is judged as suitable, satisfying or attractive’ [20]. 
For both IDIs and FGDs thematic analysis was used and 
emergent themes and sub-themes were inductively added 
to the deductive codes within the frameworks. Quotes 
were extracted to add richness and support the analysis. 
Quote labels use participant identification numbers and 
provider role to protect anonymity.
Results
A total of 43 IDIs with healthcare providers were con-
ducted across eight health facilities in the four sub-
counties (Kisumu West, Muhuroni, Nyakach and Seme); 
five of the facilities were Level 4 and three were Level 3 
facilities. The healthcare providers interviewed included: 
16 ANC nurses, 7 in-charges, 8 laboratory technicians, 7 
pharmacists, and 5 members of the County health man-
agement team (Table  1). FGDs were conducted with a 
total of 95 women attending 13 FGDs across the con-
trol and intervention groups (Table  2). The results pre-
sented here are the themes and sub-themes from both 
healthcare provider and pregnant women’s perspectives 
mapped, where applicable, across the seven feasibility 
constructs (Table 3).
Healthcare provider perspectives
Healthcare provider perceptions are explored across the 
feasibility constructs, specifically understanding accept-
ability towards key components of the intervention 
as well as how ISTp fits into routine ANC services and 
potential implementation challenges should the strategy 
be adopted. Figure  1 illustrates how the health system 
building blocks relate to the different constructs of the 
feasibility framework and indicate what elements of the 
health system need to be considered for implementation, 
in particular, products and technology, service delivery 
and human resources.
Acceptability—to what extent do healthcare providers 
accept ISTp or IPTp?
In general, healthcare providers responded positively 
towards ISTp as a MiP control strategy. Across various 
provider cadres ISTp was described as beneficial because 
women would be tested before receiving treatment, 
thereby reducing potentially unnecessary medication 
during pregnancy. In addition, some providers reported 
that women complained about having to take drugs when 
they felt fine and preferred taking drugs after testing 
positive. Many providers felt that regular testing at ANC 
Table 1 Healthcare providers interviewed by cadre and site
ANC antenatal care, ISTp intermittent screening and treatment, IPTp intermittent preventive treatment, DP dihydroartemisinin–piperaquine, SP sulfadoxine–
pyrimethamine
Healthcare provider cadre Control sites, (IPTp SP) Intervention sites, (ISTp DP) Total 
interviewed
ANC nurse 7 9 16
Facility managers 3 4 7
Laboratory technician 4 4 8
Pharmacist 4 3 7
County health management team 1 4 5
Total 19 24 43
Table 2 Focus group discussions with pregnant women by 
intervention arm
Negative: RDT negative women, positive: RDT positive women, heterogeneous: 
IPTp & ISTp
FGD focus group discussion
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Table 3 Experiences and perceptions on the feasibility of ISTp-DP vs. IPTp-SP among healthcare providers and pregnant women
ISTp intermittent screening and treatment, IPTp intermittent preventive treatment, DP dihydroartemisinin–piperaquine, SP sulfadoxine–pyrimethamine, RDT rapid 
diagnostic test, ANC antenatal care, KEMSA Kenya Medical Supplies Authority
a Health care provider perceptions of pregnant women
Feasibility framework Themes Pregnant women Healthcare providers
Sub‑themes Sub‑themes
Acceptability ISTp vs. IPTp Women want to know if they have an illness 
and either receive prevention or treat-
ment; happy to be tested, gives peace of 
mind; testing can be painful; women not 
always told what the test is for
ISTp: better to test before treating for 
malaria; reduce unnecessary medication in 
pregnancy; good to identify asymptomatic 
cases; prefer not to rely on RDTs; women 
may not want repeated testing; complaints 
of testing at every  visita
IPTp: good because focused on preven-
tion; concerns about resistance to SP; 
women accepted IPTp once benefits were 
 explaineda
IPT/IST: Women are accepting of tests and 
treatments offered at  ANCa
DP and SP Women are not always sure about taking 
drugs during pregnancy; complaints 
about side effects nausea, dizziness, head-
aches (both SP and DP but more frequent 
with SP); women happy with DP, it cured 
malaria; not happy to take SP on empty 
stomach
n/a
RDTs vs. microscopy n/a RDTs: fast, convenient and easy to use; good 
alternative to microscopy when no labora-
tory technician or electricity; not always 
accurate; they do not detect all species of 
malaria; some confusion that finger prick 
was for HIV  testinga; RDTs more accepted 






ISTp delivery at ANC Women are motivated to return to ANC to 
be tested for malaria
“One-stop-shop” is good for women, reduces 
wait times, continuity of care; better follow 
up for women receiving treatment; better 
to dispense anti-malarials at ANC; only 
pharmacy should dispense drugs; need 
adequate staffing to carry out screening 
at ANC
Demand DP vs. SP Women are motivated to attend ANC to 
receive drugs, treatments
DP: effective drug as women don’t return 
with malaria; has shorter dosing regimen 
than quinine; expensive for women to buy 
if out of stock at health facility; should only 
be used for treatment, don’t want to build 
resistance to it
SP: has been good in reducing the burden of 
MiP; concerns about resistance; good for 
prevention because can be given in one 
dose by DOT
Practicality Sustainability of RDTs and DP n/a Stock outs for both RDTs and DP; women 
may not afford DP if they need to buy from 
private providers; limited as facilities can 
only order from KEMSA
Adaptation/expansion ISTp delivery at ANC n/a Have high workloads already, RDTs in ANC 
may add to that; RDTs at ANC save time 
as we don’t need to wait from women 
to return from the laboratory; reduced 
workload for laboratory staff; happy for ANC 
providers to administer RDTs if properly 
trained
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would help identify active cases (women with malaria 
parasitaemia) as MiP is often asymptomatic.
“Interviewer[I]: How would you feel about every 
pregnant woman being given an RDT test at every 
ANC visit and if they were positive for malaria, they 
would be given an anti-malarial drug, if they were 
negative, they would not receive any anti-malar-
ial? Respondent [R]: I feel it is okay. It is the best 
approach I think…because we have actually seen 
that she is not having malaria so you don’t give the 
drug but if she is positive you treat her then she goes 
home you [know] she is going to be safe for the whole 
month before she comes back again.” IDI-14, ANC 
nurse
“I: How about the community perception of preg-
nant women, what do they say? R: I think they are 
welcoming the study because what they are saying…
ok that last time they were being given the SPs with-
out the tests but right now they are given drugs only 
when they test positive.” IDI-10, ANC nurse
Contrary views by providers focused on the use of 
RDTs for testing and the limitations with regards to accu-
racy. Some participants, mostly laboratory technicians, 
liked ISTp as a strategy but felt it should not be imple-
mented if it meant the use of RDTs instead of microscopy. 
Reliability of RDT stocks and pregnant woman confu-
sion over repeated testing were also mentioned as pos-
sible challenges to implementation. Providers perceived 
the main benefits of the current IPTp strategy to be that 
it was prevention focused and did not rely on testing. 
Concerns about growing resistance to SP were consid-
ered a downside to the current policy. Several provid-
ers described a hybrid ISTp/IPTp strategy where women 
could be tested at every ANC visit and treated if positive 
for malaria but if negative, they would still receive a pro-
phylactic dose of SP.
“I: …So how would you feel about every pregnant 
woman being given an RDT test at every ANC visit? 
R: It’s good, because there are people who have 
malaria but they don’t show symptoms. And in preg-
nancy, malaria can easily cross placenta barrier and 
infect the foetus. So I think it’s good I: So when they 
test positive what happens? R: They are treated, we 
use Duocotexin [dihydroartemisinin–piperaquine] 
right now I: How about those who turn negative? R: 
Those who turn negative, they could be given proph-
ylaxis.” IDI-27, In-charge
RDTs versus microscopy
Overall, ANC providers reacted favourably towards RDT 
use for malaria testing acknowledging that they were easy 
to use, fast and convenient. Many participants reported 
that RDTs were effective alternatives to microscopy in 
resource-limited settings, during power outages and 
when laboratory technicians were not available. However, 
the limitations of RDTs were also described with pro-
viders reporting issues with accuracy and concern over 
the devices’ inability to detect certain malaria species. 
Fig. 1 Healthcare provider perceptions across feasibility constructs [18] and health systems building blocks [19]
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Laboratory technicians, pharmacists and facility manag-
ers were more vocal about the challenges of using RDTs 
whereas the benefits of performing RDTs in ANC were 
most often reported by ANC nurses.
“I: …So what do you think about the use of RDTs 
for diagnosis of malaria as an alternative to blood 
slides? R: It’s efficient, it’s time saving and it’s appro-
priate.” IDI-3, ANC nurse
“I: What do you think about the use of RDT for diag-
nosis of malaria as an alternative to blood slide R: 
I really don’t know if RDT is 100% because I hear 
RDT will only pick specific parasites of malaria not 
all, so at one point it might give you a false reading if 
a patient is positive yet it gives negative since it has 
not picked the malarial parasites that are there in 
the blood.” IDI-37, Pharmacist
Demand—to what extent is DP perceived to have positive 
effects, to be used, and demanded by pregnant women 
compared to SP?
Healthcare providers at intervention sites responded 
positively towards the use of DP for treatment of MiP, 
finding it effective and noting that women don’t return 
with malaria if they have taken it.
“I: So what do you think about them, like let’s talk 
of DHA–piperaquine [DP]. You have used it. R: 
According to my experience it works immediately 
because after giving the mothers next visit you are 
testing them, they don’t have malaria, in fact they 
respond with the drugs, it works well.” IDI-11, ANC 
nurse
Other reported benefits of DP included a shorter dos-
ing regimen compared with quinine and mild or non-
existent side effects. It was also suggested that DP might 
be preferable to women as it was a new drug. The main 
concern with DP was that should the ANC be out of 
stock, it would be costly for women to have to buy it out 
of pocket. A facility in-charge felt that DP should not be 
used for prevention, only treatment, to avoid building 
resistance to this new drug.
Although providers acknowledged that SP had helped 
reduce the burden of MiP there was apprehension about 
growing resistance alongside reports of women returning 
with malaria despite having taken SP. However, SP was 
preferable for use as IPTp because it required only a sin-
gle dose that could be given by DOT, thereby eliminating 
compliance issues.
Adherence to drugs
There was a clear consensus among providers that longer 
dosing regimens lead to poor adherence and, as such, 
artemether–lumefantrine (AL) and DP were preferred 
to oral quinine. Providers also felt that drugs with side 
effects reduced adherence, again with some providers 
expressing a preference for DP over quinine due to the 
perception that women experienced fewer side effects 
with DP. Providers voiced their concerns about lack of 
adherence because they felt that women who did not 
adhere to the full course usually returned to the health 
facility due to relapse or complications.
“I: So what are the implications for adherence to full 
dose, or future prescriptions? R: If they don’t comply 
with the treatment and complete, they may come 
back with malaria still which has not resolved, and 
most of the time, it ends up with treatment failure. 
Poor adherence, there is treatment failure.” IDI-27, 
In-charge
Implementation—to what extent is ISTp being carried 
out in health facilities, and where?
Healthcare providers discussed the benefits of a “one-
stop-shop” at ANC where women can be tested and 
receive treatment without needing to go to the laboratory 
or pharmacy. The benefits were described as reduced 
waiting times and better follow up for treatment, as the 
first dose would be administered by DOT. Several provid-
ers mentioned that receiving all services at ANC would 
encourage women to attend as waiting times would be 
reduced.
“I: How would you feel if the pregnant mother 
attending ANC who tested positive for malaria 
were given their anti-malaria treatment by the 
ANC staff? And/or the ANC staff also implemented 
the RDTs? R: That one is very much okay it will not 
waste time for this ante natal mothers to go and line 
up again at the laboratory then you come here you 
line up go to the pharmacy you line up. These people 
are people who need support and rest so if we save 
for them time I think is okay.” IDI-13, ANC nurse
Integration—to what extent has ISTp been integrated 
into the existing system?
Overall ANC providers said they would prefer to dis-
pense the anti-malarials at ANC, however some felt 
that medications should be dispensed by the pharmacy 
and that it was only possible as long as there was suf-
ficient staff to manage it. Pharmacists preferred anti-
malarials to be dispensed by them as it was in their job 
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description and they had the proper training. Similarly, 
there was strong support by ANC nurses to carry out 
malaria testing with RDTs in ANC but again there were 
concerns about sufficient staffing and increases in work-
load, although primarily voiced by providers at the con-
trol sites. Laboratory technicians were supportive but felt 
that they should still oversee the testing for reporting and 
control purposes. A laboratory technician pointed out 
that women would still need to go to the laboratory for 
routine screening.
“R:…we would not like to give them to the ANC 
staffs…those are expensive drugs. I: But what’s the 
problem if an ANC staff gives these drugs or treat-
ment? R: There is no problem about them giving 
drugs. The issue is about management of commodi-
ties, for you to be aware of what you are doing, what 
you are using, what you have available and maybe 
the drugs are going to the right person and not any-
body else. You see we can’t have several people dis-
pensing at the facility.” IDI-40, Pharmacist
Practicality—to what extent is ISTp being carried out using 
existing resources?
Concerns about the availability of RDTs and DP were 
expressed by providers, as stock outs of both were 
reported. A further issue with regards to DP was the high 
cost of the drug and whether or not that would affect 
supply. During stock outs women are often asked to 
purchase drugs from outside the facility and some pro-
viders doubted whether women would be able to afford 
DP. Kenya Medical Supplies Authority (KEMSA) is the 
national supplier of drugs and RDTs, which limited the 
procurement options when stockouts occurred. Several 
providers mentioned trying to source drugs and RDTs 
from other facilities when they ran out.
Adaptation—to what extent have changes been made 
to existing systems to implement ISTp? Expansion—to 
what extent can ISTp be scaled up and expanded?
Healthcare providers at control sites reacted positively to 
the use of RDTs in the ANC to test pregnant women but 
only if staffing levels were sufficient. Other providers felt 
that testing pregnant women at ANC would save time as 
they would not have to wait for laboratory results. Labo-
ratory technicians supported the idea of ANC providers 
testing women with RDTs but only if they continued to 
oversee reporting and monitoring. There was broad sup-
port for ANC providers to carry out testing with RDTs as 
long as they received appropriate training.
Pregnant women perspectives
The perceptions of pregnant women towards key com-
ponents of the ISTp strategy are predominantly cap-
tured within the acceptability construct of the access 
framework, which aligns with the feasibility framework. 
Additional themes around blood testing and adherence 
fit within the feasibility constructs of acceptability and 
demand (Fig.  2). Specifically, women’s perceptions cap-
ture to what extent they are accepting of both malaria 
testing and drugs (DP) and motivated to attend ANC for 
those interventions.
Acceptability—to what extent are components of ISTp 
judged as suitable, satisfying, or attractive?
Anti‑malarial drugs and testing
Pregnant women across the groups responded favour-
ably to being tested for malaria and receiving treatment 
if positive. It also provided peace of mind to those who 
tested negative to know they did not have malaria. Gen-
erally, women wanted to know if they had any diseases 
or conditions that might compromise their health or that 
of their baby. ‘Knowing my blood level’, which refers to 
haemoglobin levels and whether or not they are anae-
mic, was frequently reported by women across all groups. 
Negative views on testing were that it was painful, a lot 
of blood was taken and sometimes the reason for the test 
was not explained.
“R2: I did not like it because even if you ask them 
what test they are doing they do not tell you and also 
even after they give you the result they are not even 
ready to tell you what it is and so you do not know 
the advantage or disadvantage.” FGD 8, IST negative
However, women were clearly willing to accept the pain 
and discomfort of finger prick tests for the benefits of 
being tested for malaria and receiving treatment.
“R4: What I did not like is that the injection was very 
painful and what I liked is that I knew my status 
and again I was happy that I had two children and I 
was going to give birth to them with the same status. 
So I liked that.” FGD 13, IST positive
When asked about their experiences taking anti-malar-
ials, pregnant women from the control group (IPTp-SP) 
shared mixed opinions. Some women were happy, as they 
did not contract malaria during their pregnancy, while 
others were not happy to have to take SP on an empty 
stomach and feared a reaction. One woman reported that 
she still got malaria despite taking SP. Women from the 
intervention group (ISTp-DP) reported being satisfied 
with DP, as it was effective and cured them of malaria.
“I: What can you say about the drugs that you were 
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given? R4: I can say that they were good. Ever since I 
finished the dose, I haven’t seen any serious signs of 
any disease in me. So I can say that they were good.” 
FGD 13, IST positive
Women in both groups reported side effects that they 
believed were caused by the anti-malarial drugs, which 
included dizziness, nausea and headaches for both SP 
and DP. Reported side effects were mentioned more often 
among women in the SP groups.
Adherence to drugs
Women reported being given a number of different drugs 
at ANC and described them largely by colour or function. 
Most women reported receiving “blood boosters” (iron 
tablets), following the dosing instructions and complet-
ing the regimen at home. A few women described not 
being able to finish as they delivered the baby before they 
finished the tablets or that they increased their appetite 
too much. One woman from an IPTp group reported 
receiving quinine tablets, but not finishing them because 
of unpleasant side effects.
“R5: I had fever sometimes during this pregnancy 
and I came to the hospital and was given thirty 
tablets of quinine. I did not finish the dose because 
whenever I took those drugs, I could feel dizzy and I 
get nauseated and sometimes I get itchy on the skin 
and my ears were blocked. So, I could not continue 
with them.” FGD 3, IPTp
Demand—to what extent is ISTp likely to be used (how 
much demand is likely to exist)?
ANC attendance
Women in both intervention groups were motivated to 
attend ANC to know their status (with regards to HIV) 
and to look for other diseases, which included getting 
tested for malaria and receiving treatment if needed or to 
prevent malaria.
“R1: I wanted to know my status on malaria because 
you know pregnant women are prone to malaria. So 
I wanted to know whether I also had malaria and 
also the condition of the child. Whether the child 
was moving or if it was not moving.” FGD 11, ISTp 
HET
Fig. 2 Analysis framework for perceptions of pregnant women
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Other important reasons for attending ANC included 
to check the health and position of the baby and receive 
drugs. Women from both intervention groups reported 
that their main reason for returning to ANC was because 
they felt an improvement in their health after receiving 
services or treatment at a previous ANC visit. Among 
women who received ISTp, malaria testing was a pri-
mary reason for returning to ANC. Interestingly, women 
reported that the main reason other women do not 
attend ANC is because they fear testing (primarily for 
HIV).
“I: Okay and why is it that many women do not go 
for the antenatal clinics? R6: Some women do not 
go to the clinic because they think that they can 
be tested and be found positive and so they are so 
afraid. I: Positive in what. R6: For the HIV test.” FGD 
2, IPTp
Other reasons reported by women for not attending 
ANC included lack of education and awareness, prefer-
ence for/influence of traditional birth attendants (TBAs) 
and the distance to reach facilities.
Health‑seeking behaviour
When asked what symptoms prompted them to seek care 
pregnant women most commonly reported ‘headaches’, 
‘feeling tired’, ‘nausea’, and ’vomiting’. ‘Suspecting malaria’ 
and ‘loss of appetite’ were also reported. Of the women 
who mentioned having experienced a fever in pregnancy, 
most of them sought treatment at the hospital. Some 
women reported other health-seeking behaviour, such 
as self-medicating from a local kiosk or pharmacy. A few 
women reported that they waited until their next ANC 
appointment and then informed the healthcare provider. 
One woman said she did not seek treatment because you 
cannot take drugs while pregnant.
“R4: What can make someone to leave the house 
to go to the hospital is when sometimes you feel so 
tired or you have some abdominal pains. Maybe you 
feel you are tired like you have malaria. You know 
you cannot just go to the shop and buy drugs; you 
will have to go to the hospital so that you are tested. 
Maybe you feel pain in the lower abdomen. You will 
have to come to the hospital so that you are checked 
and given the correct drug for the problem.” FGD 6, 
ISTp positive
Integration of qualitative and quantitative findings
Each of these strategies is composed of several delivery 
steps, however the ISTp-DP strategy has more steps and 
is more complex to deliver. Healthcare providers were 
supportive of the test and treat (ISTp) strategy for MiP 
and appreciated that administering RDTs at ANC would 
improve the continuity of care for pregnant women. This 
was reflected in the findings from the quantitative study 
that shows a high proportion (90%) of eligible women 
attending ANC were tested with an RDT and 71% of 
women that tested positive were given the correct dose 
of DP [17]. There were however issues with healthcare 
provider adherence to other components of the ISTp 
strategy, with only 31% of pregnant women who were 
given DP receiving the first dose by DOT and only 6% of 
women reported being given instructions by the provider 
on how to take the remaining doses. Healthcare provid-
ers discussed the challenges with adherence to multiday 
treatment regimens that produced side effects (such as 
with quinine), and many felt that the shorter regimen 
of DP and relatively few associated side effects meant it 
may be better tolerated by women. Providers also shared 
their perception that women prefer to take drugs when 
used for treatment rather than for prevention and felt 
confident women would take the doses as required. Some 
providers indicated that women reportedly did not like to 
take drugs if they were not ill and welcomed treatment 
only if they tested positive. This view was confirmed 
by pregnant women who reported being motivated to 
attend ANC to get tested to know if they have malaria 
and receive treatment if positive. Provider adherence to 
DOT was higher among women receiving standard care 
of IPTp with SP (57%) [17]. That provider adherence to 
DOT was higher when delivering IPTp-SP than ISTp-DP 
aligns with the perception of providers that women are 
less motivated to take drugs, such as SP when they were 
not ill.
Discussion
This is the first published study on healthcare provider 
and pregnant women perspectives regarding the feasi-
bility of implementing ISTp-DP in an operational setting 
in sub-Saharan Africa. The concept of providing treat-
ment after a positive test result was widely welcomed by 
healthcare providers, who highlighted the reduction of 
unnecessary exposure to anti-malarials during pregnancy 
and the growing threat of resistance to SP used for IPTp. 
Both strategies were seen to deal with the asymptomatic 
nature of MiP but some providers thought preventive 
treatment was the best way to ensure women were pro-
tected, while others preferred regular screening. There 
was interest in a hybrid strategy that provided IPTp-SP to 
women who tested RDT negative.
Pregnant women were accepting of finger prick tests 
for malaria and reacted positively towards DP as a treat-
ment option. Women were motivated to attend ANC to 
detect or prevent illness and look after the health of their 
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baby, which included undergoing diagnostic tests and 
receiving drugs, accepting both as part of the ANC pack-
age. Women in both groups were generally accepting of 
ISTp and IPTp suggesting that they were less concerned 
with specific interventions and more focused on the 
overall health benefits of ANC, a finding also described 
in a study of pregnant women’s acceptability of ISTp ver-
sus IPTp from Ghana [21] and supported by the findings 
in the acceptability trial [12]. Despite this general accept-
ability by both healthcare providers and pregnant women 
towards ISTp, there remain legitimate concerns with 
regards to key elements of the strategy and how those 
challenges may affect implementation and scale up, in 
particular ANC provider performance, such as deliver-
ing DP by DOT. Should ISTp become policy, intervention 
studies will be needed to explore how these challenges 
can be overcome.
The low sensitivity and specificity of the available RDTs 
was seen as a major stumbling block to the implementa-
tion and scale-up of ISTp. Concerns about only detect-
ing P. falciparum species were raised along with reports 
of false positives if women had recently had malaria and 
been treated. These challenges were most often described 
by laboratory technicians, pharmacists and facility in-
charges, whereas front line ANC providers focused on 
the benefits of using RDTs, enabling fast, easy testing 
of pregnant women in the ANC, a finding supported by 
an acceptability study involving ISTp in Indonesia [13]. 
However, this differs slightly from the acceptability study 
of these same strategies but conducted in the trial setting 
[12], that noted all cadres of health workers preferred 
the use of microscopy. Interestingly, it would seem that 
despite the known limitations of RDTs, ANC providers in 
this study felt that the benefits of reducing wait times and 
providing continuity of care outweighed those concerns. 
This is encouraging given that more sensitive RDTs are 
now becoming available such that the role of ISTp or a 
hybrid strategy may be revisited.
Pregnant women were willing to have blood taken if it 
meant detecting an illness and receiving treatment. Many 
acknowledged that the finger pricks were painful but that 
the benefits outweighed the discomfort. This is in line 
with findings from northern Ghana and Malawi suggest-
ing that women were motivated to endure blood tests 
in order to find out if they had malaria [11, 22]. Find-
ing out about their health status was a high priority for 
most women who participated in the discussions. Among 
women in the intervention group (ISTp), being tested for 
malaria was a primary motivation to return for subse-
quent ANC visits, a finding supported by an ISTp accept-
ability study in Malawi [11]. Healthcare providers also 
believed that women were willing to accept the blood 
test, as they trusted the staff and services offered at ANC.
Both providers and pregnant women perceived DP to 
be an effective anti-malarial with some healthcare pro-
viders expressing a preference to DP over SP. Concerns 
about growing SP resistance led some providers to sug-
gest that shifting to ISTp would help relieve drug pres-
sure. Fewer side effects were reported by women taking 
DP compared with SP, although the side effects them-
selves were similar, mainly dizziness, nausea, and head-
aches. The experience of side effects can affect both 
acceptability of the drug and adherence to the dosing 
regimen. That women reported few or mild side effects 
to DP is encouraging when considering that women need 
to complete the 2nd and 3rd dose at home. Providers are 
sometimes skeptical of whether or not women complete 
doses of medication at home. In Ghana, providers sug-
gested that women would discard the SP tablets if given 
to take at home [22]. Women expressed dislike for having 
to take SP on an empty stomach fearing side effects. This 
finding was documented in a large systematic review on 
barriers and facilitators to MiP interventions [23] and a 
study in Mali found that healthcare providers sometimes 
avoided giving IPTp for this reason [24]. However, across 
both IPTp and ISTp discussion groups women reported 
seeing the health benefits of taking anti-malarial medica-
tions and accepted what was given to them by the ANC 
providers. Adherence was only an issue for one woman 
who was given quinine tablets for malaria treatment and 
didn’t finish due to side effects.
Key themes to consider on the delivery of ISTp through 
the ANC platform include: task shifting from the labora-
tory and pharmacy to ANC nurses, weighing the addi-
tional workload for ANC providers against the benefits 
of providing a ‘one-stop-shop’ at ANC and the sustain-
ability of RDTs and DP considering the cost and supply 
chain issues. Integration of ISTp into routine ANC eluci-
dated mixed views from providers depending largely on 
the cadre. Issues with RDT proficiency and adherence to 
giving the first dose by DOT identified in the quantita-
tive study reflects the reservations by pharmacists about 
nurses prescribing anti-malarials. This suggests that both 
pre- and in-service training of ANC providers along with 
supportive supervision would be required. Specifically, 
pharmacists could be involved in the training and over-
seeing of DP provision until confidence in the delivery of 
the first dose by DOT and adequate instructions for sub-
sequent doses was enhanced.
Front-line ANC nurses were positive about test-
ing women with RDTs and dispensing anti-malarials at 
ANC as they felt it would improve continuity of care and 
reduce waiting times. This was supported by the quanti-
tative findings that found testing in the ANC to be effi-
cient as women were promptly  given their results and 
91% of women who tested positive for malaria were given 
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DP immediately [17]. Although conversely, the study 
found that only 31% of women received the first dose of 
DP by DOT, which may reflect the perception by provid-
ers that women are motivated to take anti-malarials after 
they receive a positive RDT result and therefore may not 
be as concerned about giving the first dose by DOT. In 
addition, women may refuse DOT due to concerns about 
taking drugs generally on an empty stomach, a finding 
consistent with other studies [23, 24]. ANC nurses at 
control sites (IPTp) were more likely to express concerns 
about increased workload of using RDTs for malaria 
screening and felt that sufficient staffing levels needed to 
be achieved before ISTp could be implemented. That pro-
viders at implementation sites did not express concerns 
about additional workload could mean that either admin-
istering RDTs at ANC did not significantly increase their 
workload or that they perceived the benefits of increased 
continuity of care to outweigh the additional effort of 
testing women.
Several providers suggested a hybrid strategy with 
women tested for malaria at every ANC visit and treated 
if positive, as per ISTp, with any woman testing nega-
tive receiving IPTp-SP to ensure complete protection. 
This finding was also reported in the acceptability study 
[12], with providers reluctant to completely let go of a 
prevention strategy. The proposal for a hybrid strategy 
may reflect the general lack of confidence in RDT or sim-
ply a reluctance to shift paradigms from prevention to 
treatment.
The RCT of ISTp-DP versus IPTp-SP showed that 
ISTp was inferior to IPTp and should not replace IPTp 
at current levels of RDT sensitivity [6]. Since the trial, 
more sensitive RDTs have become available such that 
the global community may revisit the ISTp strategy 
in some settings, for example in areas with decreased 
malaria transmission when IPTp would no longer be 
cost effective, or the hybrid strategy, for areas with high 
levels of SP resistance [25]. The findings of this study 
enhance the understanding of healthcare provider and 
pregnant women’s perceptions of test and treat strat-
egies versus prevention for the control of malaria in 
pregnancy in routine health care settings.
Strengths and limitations
Focus group discussions with pregnant women relied 
on historical reports of ANC visits from the current or 
past pregnancies, although even if some facts are recall-
dependent the perspectives and feelings captured are 
likely to be genuine. The degree to which women feel 
comfortable sharing their experiences and opinions in a 
group setting may affect their willingness to give truth-
ful accounts. Social desirability bias may apply to both 
women and providers interviewed, who may have given 
answers they feel the interviewer wanted to hear. Find-
ings from this study help explain and support the quan-
titative results from the parallel study thus strengthening 
the overall conclusions.
Conclusions
This study explores healthcare provider and pregnant 
women perspectives on factors that could affect the 
implementation of ISTp-DP in routine settings. In gen-
eral, healthcare providers were accepting of ISTp as a 
potential alternative to IPTp-SP, a finding reflected in 
the parallel quantitative study, but many recognized the 
limitations of ISTp at the current levels of RDT sensi-
tivity. Pregnant women acknowledged the benefits of 
being tested and treated for malaria. DP was well toler-
ated by women, who reported minimal side effects. In 
addition, DP was seen as an effective anti-malarial by 
healthcare providers, especially with the growing threat 
of SP resistance. Concerns about RDT and DP avail-
ability could represent legitimate barriers to effective 
implementation. These findings will help inform policy 
makers when considering the feasibility of implement-
ing ISTp-DP alone or in combination with IPTp-SP.
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